DATA SHEET

Reagent: M311 Cells

Catalog Number: 1295

Lot Number: 99015

Release Category: C

Provided: 7 x 10^6 cells/vial.

Propagation Medium: RPMI 1640, 90%; fetal bovine serum, 10%.

Freeze Medium: RPMI 1640, 70%; fetal bovine serum, 20%; DMSO, 10%.

Growth Characteristics: Split twice weekly 1:10. M311 cells are stable and do not need to be maintained in selection medium. If growth in selection medium is desired, propagation medium containing 700 µg/ml G418 should be used. Wash the thawed cells in propagation medium and centrifuge for 10 minutes at 1000 rpm before seeding the cells in a culture flask.

Sterility: Negative for bacteria, fungi and mycoplasma.

Description: M311 cells contains stably integrated, silent copies of the HIV-1 LTR promoter linked to the CAT gene.

Special Characteristics: This cell line was generated by infection of Molt-4 cells with a helper-free recombinant retroviral vector containing the HIV-1 LTR-CAT gene construct. M311 was selected in geneticin (G418) under limiting dilution and is a sensitive indicator cell line for HIV-1 Tat. When infected by HIV-1, M311 produces high levels of chloramphenicol acetyl transferase (CAT)\(^1,2\).

Recommended Storage: Liquid nitrogen.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Contributor: Dr. Barbara K. Felber and Dr. George N. Pavlakis.

References:

2 Schwartz S, Felber BK, Fenyo EM, Pavlakis GN. Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. *Proc Natl Acad Sci USA* **86**:7200-7203, 1989.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: M311 Cells from Dr. Barbara K. Felber and Dr. George N. Pavlakis." Also include the references cited above in any publications.

An NCI patent application has been filed on the use of the cell line M311.

Corporate requests should be directed in writing to: B.K. Felber or G.N. Pavlakis, National Cancer Institute, FCRDC, ABL-Basic Research Program, P.O. Box B/Building 539, Room 121, Frederick, Maryland 21702-1201. Phone: (301) 846-1474, FAX (301) 846-5991.

Last Updated: July 02, 2018